A Limited Defense of Clinical Placebo Deception
Adam J. Kolber
Brooklyn Law School
Yale Law & Policy Review, Vol. 26, 2007
San Diego Legal Studies Paper No. 07-87
Placebo treatments, like sugar pills and saline injections, are effective in treating pain and perhaps a host of other conditions. To use placebos most effectively, however, doctors must mislead patients into believing that they are receiving active medications. While placebo deception is surprisingly common, its legality has rarely been tested. In November 2006, the American Medical Association (AMA) adopted a new ethics provision categorically prohibiting doctors from using placebos deceptively. In so doing, the AMA shifted the legal landscape, making it almost certain that courts will decide that placebo deception violates informed consent requirements.
I argue that the AMA's new policy is overbroad, insensitive to patient preferences, and likely to have unforeseen consequences. While deception is often exploitative, placebo deception can genuinely benefit patients. Absent stronger evidence to justify a ban than we currently have, deceptive placebos should be treated as scarce medical resources--used sparingly but not categorically prohibited.
Number of Pages in PDF File: 60
Keywords: Bioethics, Placebo, Deception, Health Law
Date posted: March 3, 2007 ; Last revised: July 27, 2015